Bora Pharmaceuticals is pushing deeper into specialty pharmaceuticals with its latest US acquisition, agreeing to buy New Jersey-based rare disease drug developer Pyros for $27.25 million. The deal marks the Taiwanese drugmaker’s shift from generic medicines toward patented treatments.
The purchase gives Bora control of Pyros’s VIGAFYDE oral solution for infant spasms, which received FDA approval in June as the first ready-to-use liquid formulation of vigabatrin in 15 years. The treatment launched commercially in September through Bora’s USL Pharmaceuticals unit.
The transaction, expected to close in the fourth quarter, is Bora’s third major US deal this year following its acquisitions of USL Pharmaceuticals and an Emergent BioSolutions sterile injection facility. The combined value of these purchases reaches NT$8.58 billion ($274 million).
CEO Bobby Sheng indicated the Pyros acquisition strengthens the company’s position in pediatric neurology by combining Pyros’s rare disease expertise with USL’s established presence in the field. The deal also expands Bora’s “Promise of Support” program for rare disease patients.
Founded in 2017, Pyros specializes in developing treatments for rare neurological conditions in infants and children. Its products have received orphan drug designation from the FDA.
